Blis Technologies Limited · NZX:BLT
Blis Technologies — Shareholder Meeting (August 2023)
27 slides from Blis Technologies's shareholder meeting presentation, Aug 17, 2023
Slide 1: Annual Shareholder Meeting 2023
ANNUAL SHAREHOLDER MEETING 2023 17 AUGUST 2023
Slide 2: Attendees Question and Voting Process
ATTENDEES QUESTION AND VOTING PROCESS Voting and asking questions Voting Card Question box 1
Slide 3: Meeting Agenda
MEETING AGENDA BUSINESS OF THE MEETING ACTING CHAIRPERSON’S ADDRESS • Amelia (Aimee) McCammon CHIEF EXECUTIVE OFFICER’S ADDRESS • Brian Watson ORDINARY RESOLUTIONS • That Dr Jörn Andreas be elected as a director • Directors authorised to fix the auditors remuneration OTHER BUSINESS
Slide 4: Board of Directors
BOARD OF DIRECTORS AMELIA (AIMEE) GEOFFREY (GEOFF) ANTONY (TONY) DR BARRY DR JÖRN DR ALISON MCCAMMON PLUNKET BALFOUR RICHARDSON ANDREAS STEWART Acting Chair, Independent Chair, Independent Deputy Chair, Independent Independent non-executive Non-executive director Independent non-executive non-execut
Slide 5: Disclaimer
DISCLAIMER INFORMATION In making an investment decision, investors must rely on may involve significant elements of subjective judgement their own examination of the Company, including the and assumptions as to future events which may or may The information in this presentation is an overview and me
Slide 6: Summary FY23
SUMMARY FY23 $ 10.2m $ 0.6m $ 1.4m + 11% + 21% TRADING EBITDA LOSS NET DEFICIT B2B B2C REVENUE 2HY23 REVENUE REVENUE positive EBITDA +14% on prior year
Slide 7: Strategy Reset
STRATEGY RESET RENEWED FOCUS TO RETURN TO PROFITABILITY • B2B and global • B2C where we have an partnerships established presence • R&D innovation pipeline
Slide 8: CEO Address
CEO ADDRESS BRIAN WATSON Chief Executive Officer (CEO)
Slide 9: The Blis Leadership Team
THE BLIS LEADERSHIP TEAM BRIAN WATSON RICHARD WINGHAM DR JOHN HALE JENNIFER WALKER Chief Executive Officer (CEO) Chief Financial Officer (CFO) Chief Technology Officer (CTO) Chief Revenue Officer (CRO)
Slide 10: Probiotic Supplements Market Overview
PROBIOTIC SUPPLEMENTS MARKET OVERVIEW FORECAST CAGR GLOBAL PROBIOTIC (2021 – 2026) SUPPLEMENTS MARKET 2022* Total value over US$8.2b North America -1% Asia Pacific 10% 6.7% North America Europe 3% 21.7% Asia Pacific 39.5 % Europe Total Global Market 3.7% ROW 32.0 % * Euromonitor International report
Slide 11: Summary FY23
SUMMARY FY23 REVENUE (NZ$M) EBITDA (NZ$M) $12.0 $10.6m 10.6m $ $12.0 10.2m $ $10.0 $9.0m $9.0 $8.2m $8.0 $6.0 $6.0 $5.3m $4.0 $2.0 $2.1m $0.9m $1.0m $3.0 $0.0 -$2.0 -$0.4m -$0.6m $0.0 -$2.1m FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23
Slide 12: Summary FY23 Continued: Revenue Breakdown
SUMMARY FY23 CONTINUED REVENUE BREAKDOWN (NZ$M) REVENUE BREAKDOWN (NZ$M) By Category (historic) By Category (new structure) $12.0 $12.0 $10.0 $10.0 $8.0 $8.0 $6.0 $6.0 $4.0 $4.0 $2.0 $2.0 $0.0 $0.0 FY18 FY19 FY20 FY21 FY22 FY23 FY18 FY19 FY20 FY21 FY22 FY23 Ingredient Finished Product Licencing B2B
Slide 13: Summary FY23 Continued: Revenue by Region
SUMMARY FY23 CONTINUED REVENUE BY REGION (NZ$M) $6.0 $5.0 $4.0 $3.0 $2.0 $1.0 $0.0 FY21 FY22 FY23 FY21 FY22 FY23 FY21 FY22 FY23 Asia Pacific Europe North America
Slide 14: FY23 Summary
FY23 SUMMARY STRATEGY RESET PROBI PARTNERSHIP R&D • Aligned staff to B2B and • Probi supply of licensed BLIS • Completed 2 R&D collaboration B2C structure K12™ and BLIS M18™ projects with Probi • Narrowed B2C markets and • First royalty payments • 12 new publications on BLIS completed transition pla
Slide 15: Probi Strategic Partnership
PROBI STRATEGIC PARTNERSHIP PRIMARY OPPORTUNITIES PROGRESS • Probi supply of licensed BLIS K12 and BLIS M18 • First royalty payments and a • Substantial revenue growth An expanded promising start to 1Q24 and increased market portfolio to sell • 2 R&D projects completed, penetration to a strong exist
Slide 16: Strategy Reset
STRATEGY RESET FOCUS ON WHAT WE DO BEST DELIVERED THROUGH • B2B opportunities and licensing of our technology o Strategic partnership with Probi Developing breakthrough • B2C in those markets where we have an established presence probiotic solutions for the • R&D and our product innovation pipeline
Slide 17: R&D Focus
R&D FOCUS BUILDING ON OUR STRENGTH OF PROBIOTIC INNOVATION Early research and New Product New IP / Patents evidence base Development Upper Anti-viral Anti-viral Anti-viral Respiratory Pre and post biotics Synbiotic Fast melt Health Links with Dental Oral formulation general health Toothpaste Health
Slide 18: Strategy Reset - One Year On
STRATEGY RESET - ONE YEAR ON • Business unit structures • Revenue growth in B2B based on B2B and B2C and B2C channels • New skincare • 2HY23 EBITDA positive, opportunity announced 1Q24 breakeven in line August 2023 with expectations
Slide 19: Q1 Update
Q1 UPDATE UNAUDITED RESULTS FOR THE QUARTER ENDING 30 JUNE 2023 (Q1 FY24) Revenue and EBITDA are in-line with our expectations $2.8m TOTAL REVENUE FOR THE QUARTER $0.0m EBITDA BREAKEVEN OUTLOOK • We continue to see the refreshed strategy and business model drive revenue growth and support our journe
Slide 20: Summary
SUMMARY The business Probi - long Our strength Margin from model - B2B term strategic - probiotic established selling and partnership for innovation B2C markets partnerships growth
Slide 21: Questions
QUESTIONS Wait for the microphone STATE YOUR NAME AND WHETHER YOU ARE A SHAREHOLDER OR PROXY HOLDER.
Slide 22: Attendees Question Process
ATTENDEES QUESTION PROCESS Voting and asking questions Voting Card Question box 1
Slide 23: Resolutions
RESOLUTIONS Wait for the microphone STATE YOUR NAME AND WHETHER YOU ARE A SHAREHOLDER OR PROXY HOLDER.
Slide 24: Attendees Voting Process
ATTENDEES VOTING PROCESS Voting and asking questions Voting Card Question box 1
Slide 25: Resolution 1
RESOLUTION 1 THAT DR JÖRN ANDREAS BE ELECTED AS A DIRECTOR OF THE COMPANY Wait for the microphone STATE YOUR NAME AND WHETHER YOU ARE A SHAREHOLDER OR PROXY HOLDER.
Slide 26: Resolution 2
RESOLUTION 2 THAT THE DIRECTORS BE AUTHORISED TO FIX THE REMUNERATION OF THE AUDITORS FOR THE ENSUING YEAR Wait for the microphone STATE YOUR NAME AND WHETHER YOU ARE A SHAREHOLDER OR PROXY HOLDER.
Slide 27: General Business
: BLIS’ GENERAL BUSINESS
Blis Technologies — Shareholder Meeting (August 2023) on 6ix